查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
化療引起的周圍神經病變治療的全球市場-2022-2029
市場調查報告書
商品編碼
1140674

化療引起的周圍神經病變治療的全球市場-2022-2029

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

研發的持續增長將在預測期內繼續支持市場增長。

在化療引起的周圍神經病變市場上運營的公司正在不斷開發有效的藥物和藥物來管理化療。體內的癌細胞強調給予小劑量的治療周圍神經病變的藥物。因此，展望未來，全球化療引起的周圍神經病變市場的主要市場參與者正在加大對腫瘤學研究的投資。例如，2021 年 12 月，Paxman KTP 創造了一種新設備來防止化療副作用 CIPN。哈德斯菲爾德大學和 Paxman 合作開發了一種醫療冷卻系統，以預防化療引起的周圍神經病變 (CIPN)。 CIPN 會導致接受化療的患者四肢進行性且通常是不可逆的疼痛和敏感，從而導致治療延誤和停藥。

此外，與研究機構的合作正在推動全球市場的增長。哈佛健康評論提供有關神經系統疾病管理和治療的相關信號。許多化療誘導的周圍神經病變市場公司預計將與哈佛研究獎學金合作，並從合作研究中受益。從化療引起的周圍神經病變的角度來看，哈佛醫學院的見解已經使許多公司、研究單位和泌尿系統疾病受益。

但是，與治療相關的副作用可能會阻礙全球化療引起的周圍神經病變市場。

地理滲透率

在整個預測期內，北美主導著全球市場。

該研究按地區分析了全球市場中化療引起的周圍神經病變市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

北美在全球化療引起的周圍神經病變市場佔據主導地位，預計在預測期內將保持其地位。美國為 2022 年北美化療引起的周圍神經病變治療市場做出了貢獻。各種癌症的發病率和患病率的增加增加了對抗癌藥物的需求。與末期使用的其他治療選擇（例如免疫治療和靶向治療）相比，這種增長是由於癌症治療早期階段的化療。

預計在預測期內，亞太地區化療引起的周圍神經病變市場將顯著增長。這種增長可歸因於該地區醫療保健基礎設施的快速發展和宣傳活動的增加。此外，印度、中國、新加坡和馬來西亞等新興國家醫療旅遊的增長估計也對全球化療引起的周圍神經病變市場產生積極影響。

競爭格局

化療引起的周圍神經病變市場是一個競爭激烈的市場。化療引起的周圍神經病變治療的主要參與者為全球市場的增長做出了貢獻，包括 Regency Pharmaceuticals、Nemus Bioscience Inc、PledPharma、Immune Pharmace Inc.、DermaXon LLC。領先公司正在為全球化療引起的周圍神經病變市場的增長採用新產品發布和擴張戰略。 2022年3月，旭化成製藥宣佈在日本和美國用於預防化療引起的周圍神經病變（CIPN）的ART-123（通用名：thrombomodulin alfa，日本商品名：recomodulin Note）將成為全球首個1 期試驗。宣布開始在患有以下疾病的患者中進行藥物管理試驗該試驗將與 Asahi Kasei Corporation 的全資子公司 Veloxis Pharmaceuticals, Inc. 聯合進行。 2021年9月， Novaled 收購了 Metys Pharmaceuticals ，以擴大其在慢性疼痛中的非鴉片類藥物候選藥物的管道。此次收購旨在為患者提供有效且耐受性良好的藥物，同時滿足對非成癮療法的迫切需求。

COVID-19 的影響將對全球化療引起的周圍神經病變市場產生負面影響。

COVID-19 的爆發無疑影響了全球化療引起的周圍神經病變市場。封鎖迫使診斷出新的癌症病例，因此在 COVID-19 流行期間降低了化療引起的周圍神經病變治療的採用率。因此，化療引起的周圍神經病變市場預計在 2020 年將大幅下降。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品劃分的市場細分
  • 按應用劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
  • 促進因素
    • 癌症發病率增加
    • 提高新興國家的意識
  • 抑制因素
    • 治療的副作用
  • 商機
  • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST 分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品分類

  • 鈣通道 A2-delta 配體
  • 抗憂鬱藥
  • 鴉片類藥物
  • 其他

第 8 章按應用程序

  • 白金配方
  • 紫杉烷
  • 長春花生物鹼
  • 其他

第 9 章最終用戶

  • 醫院和診所
  • 癌症中心

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 12 章公司簡介

  • Asahi Kasei Pharma Corp
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Regency Pharmaceuticals
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Nemus Bioscience Inc
  • PledPharma
  • Sova Pharmaceuticals Inc
  • DermaXon LLC
  • Immune Pharmaceuticals Inc.
  • Solasia Pharma K.K.

第 13 章 DataM

簡介目錄
Product Code: DMHCIT3008

Market Overview

Chemotherapy-Induced Peripheral Neuropathy Treatment Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 5 % during the forecast period (2022-2029).

Chemotherapy-induced peripheral neuropathy is a serious clinical problem induced by several chemotherapeutics drugs or cytotoxic drugs such as platinum, taxanes, and vinca alkaloids eribulin, epothilones, and bortezomib. These drugs cause different pathological problems to the neurons. The pathological problems lead to the degeneration of peripheral sensory and motor nerves and cause patients to present with sensory disturbances, balance problems, or weakness. The technological advancement in the treatment and diagnosis of cancer and the rising incidence of chemotherapy-induced peripheral neuropathy is expected to propel the market growth. Moreover, the increasing demand for cost-efficient therapeutics in emerging regions is an opportunity for market growth.

Market Dynamics: Continuous rise in R&D will continue supporting the growth of the market during the forecast period.

The companies operating in the chemotherapy-induced peripheral neuropathy market are constantly developing efficient drugs and medications to manage chemotherapy. Cancerous cells in the body make it critical to administer minor doses of drugs for peripheral neuropathy. Henceforth, the key market players in the global chemotherapy-induced peripheral neuropathy market are ramping up their oncological research investments. For instance, in December 2021, Paxman KTP created a new device to prevent chemotherapy side-effect CIPN. University of Huddersfield and Paxman partnered to develop a medical cooling system to prevent Chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes progressive and often irreversible pain or sensitivity in the hands and feet of patients undergoing chemotherapy leading to delays and discontinuation of treatment.

Also, collaboration with research institutes is driving the growth of the global market. Harvard Health Reviews have been offering relevant signals for the management and treatment of neuropathy. Numerous chemotherapy-induced peripheral neuropathy market companies are expected to collaborate with Harvard's research fraternity to reap the benefits of collaborative research. The Harvard Medical School insights have already helped numerous companies, research units, and chemotherapy-induced peripheral neuropathy'stand nature and uropathy.

However, the adverse effect associated with the treatment may hamper the global chemotherapy-induced peripheral neuropathy treatment market.

Market Segmentation: The antidepressants segment accounted for the highest share in global chemotherapy-induced peripheral neuropathy treatment market.

Antidepressant contributes the major share of the chemotherapy-induced peripheral neuropathy treatment market. It has a clinically meaningful effect on chemotherapy-induced peripheral neuropathy. Adjunct treatment options for chemotherapy-induced peripheral neuropathy include a topical analgesic, a tricyclic antidepressant, an anticonvulsant, or an SNRI. Therefore, realizing the potential benefits of chemotherapy-induced peripheral neuropathy as an antidepressant will drive market growth during the forecast period.

The chemotherapy-induced peripheral neuropathy treatment market has been classified into platinum agents, taxanes, vinca alkaloids, and others based on the application. The Platinum Agents segment held a significant market share in the global chemotherapy-induced peripheral neuropathy treatment market in the forecast period. The major application of platinum agents is the chemotherapy-induced peripheral neuropathy treatment market. Platinum agents (carboplatin, cisplatin, and oxaliplatin) are a class of chemotherapy agents with a wide range of activity against several solid tumors. Toxicity to the peripheral nervous system is the key dose-reducing toxicity of a few platinum drugs of clinical interest. Among the platinum compounds, cisplatin is considered the most neurotoxic, inducing mainly sensory neuropathy of the upper and lower extremities.

Geographical Penetration: North America dominated the global market throughout the forecast period.

Based on geography, the study analyzes the chemotherapy-induced peripheral neuropathy treatment market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America dominated the global chemotherapy-induced peripheral neuropathy treatment market and is expected to retain its position during the forecast period. The U.S. contributed over xx % to the North American chemotherapy-induced peripheral neuropathy treatment market in 2022. The increase in the incidence and prevalence rate of different cancer has led to a rise in demand for cancer drugs. This growth is due to chemotherapy in earlier cancer treatment stages compared to other therapy options such as immunological therapy drugs and targeted therapy drugs used in the late stage.

The Asia Pacific is estimated to grow considerably in the chemotherapy-induced peripheral neuropathy treatment market during the forecast period. This growth can be accredited to the rapidly developing healthcare infrastructure and rising awareness programs in this region. Further, growing medical tourism in developing countries such as India, China, Singapore, and Malaysia is also estimated to positively youth the global chemotherapy-induced peripheral neuropathy treatment market.

Competitive Landscape:

The chemotherapy-induced peripheral neuropathy treatment market is highly competitive. The key chemotherapy-induced peripheral neuropathy treatment players contributing to the global market's growth market include Regency Pharmaceuticals, Nemus Bioscience Inc, PledPharma, Immune PharmaceIncnc., and DermaXon LLC. The major players are adopting new product launches and expansion strategies for global growth in the chemotherapy-induced peripheral neuropathy treatment market. In March 2022, Asahi Kasei Pharma announced that a drug administration study began for the first patient in the Japan-US international phase 1 study of ART-123 (generic name: thrombomodulin alfa; marketed as Recomodulin Injection in Japan) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). This study is performed jointly with Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary of Asahi Kasei Corp. In September 2021, Novaremed acquired Metys Pharmaceuticals to expand its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications. This acquisition aims to deliver effective and well-tolerated medications to patients while simultaneously addressing the urgent need for non-addictive treatments.

COVID-19 Impact: Negative impact on the global chemotherapy-induced peripheral neuropathy treatment market.

The outbreak of COVID-19 has certainly impacted the global chemotherapy-induced peripheral neuropathy treatment market, as the lockdown has compelled the diagnosis of new cancer cases, which in turn has derailed the adoption rate of chemotherapy-induced peripheral neuropathy treatment amidst the COVID-19 pandemic. Therefore, the chemotherapy-induced peripheral neuropathy treatment market is expected to foresee a considerable decline in 2020.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by End-Users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Increasing incidence of cancer
    • 4.2.2. Rising awareness in emerging economies
  • 4.3. Restraints:
    • 4.3.1. Side-effects of treatment
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Calcium Channel A2-delta Ligands*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Antidepressants
    • 7.3.3. Opioids
    • 7.3.4. Others

8. By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.3. Market Attractiveness Index, By Application Segment
    • 8.3.1. Platinum Agents*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Taxanes
    • 8.3.3. Vinca Alkaloids
    • 8.3.4. Others

9. By End-Users

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment
  • 9.3. Market Attractiveness Index, By End-Users Segment
    • 9.3.1. Hospitals & Clinics*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Cancer Centers

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. The U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. The U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. The Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Asahi Kasei Pharma Corp*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Regency Pharmaceuticals
  • 12.3. MAKScientific LLC
  • 12.4. Metys Pharmaceuticals AG
  • 12.5. Nemus Bioscience Inc
  • 12.6. PledPharma
  • 12.7. Sova Pharmaceuticals Inc
  • 12.8. DermaXon LLC
  • 12.9. Immune Pharmaceuticals Inc.
  • 12.10. Solasia Pharma K.K.

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us